Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer High-quality end-of-life cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback